Our articles

At ELRIG Drug Discovery 2026, our speakers explored the creative strategies they’re using to develop the next generation of precision medicines.

AI regulations remain limited, despite warnings of catastrophe. The pharma industry shows why we shouldn’t wait for disaster before acting.

This Financial Times piece, which opens with one father’s experience of losing his son to a brain tumour, shows why C-Further matters.

After a career in drug development, how does the industry look through experienced eyes? We spoke to Rob Williams to find out.

Gillian Farnie talks about how her new Therapeutic Translation Team can get research to have real impact on patients.

This Pride Month, we brought together four leaders from research, healthcare and industry to discuss breaking barriers to LGBTQ+ equity in cancer.

Despite questions over efficacy and delivery, in-vivo CAR-T presents a hugely exciting opportunity. Is this a genuine breakthrough or a false dawn?

Vivek Singh shares how the Venture Builder Incubator has supported the development of his innovation to aid the early detection of liver cancer.

Marco Purbhoo from MiNK Therapeutics talks about biotech’s role in paediatric oncology and how to attract private sector investment in the area.

In the build up to AACR, we spoke to current AACR President Lillian Siu about the things drug-discovery gets wrong about clinical deployment.

Gaps in early-stage funding are holding back the potential of UK research, but alternative investors is beginning to close them.

China’s emergence as a life sciences superpower is reshaping the industry, but what does this mean for the UK’s researchers, spin-outs and patients?

Siftr Bio CEO Dan Lucy explains how a chance collaboration, a supportive ecosystem, and stepping away from academia, set his start-up in motion.

Xterna CEO Jessica Corry spoke to Liv Shovlin about starting her entrepreneurial journey and getting comfortable with the uncomfortable.

A summary of UKRI's independent review of investment into UK spin-outs.

Tim Bodicoat ponders the thawing of the biotech winter and asks if the market can ever tell you if it’s the right time to launch a start-up.

Tim Yap spoke to Sarah Halford about running clinical trials on both sides of the Atlantic and how the global community can work together.

From fundamentals to translation – Steve Pollard’s research into transcription factors driving brain development has been quite the ride.

Navigating the innovation ecosystem can be daunting, but it is the only way that entrepreneurs can turn scientific discoveries into patient benefit.

Cytospire CEO Natalie Mount shares what she loves about start-ups, how the industry has changed, and her advice to entrepreneurs. 

How the Newcastle Drug Discovery Group blends the best of both academia and industry to bring about its success.

Stephanie Droop, Nikki Graham, Ali Taj, Solmaz Eradat Oskoui and Ioanna Nixon share their experiences of the Venture Builder Incubator.

Pathway Bio co-founder Bobby Kaura shares his experience of launching his start-up and participating in the KQ Labs entrepreneurial programme.

Joe Day speaks with Technology Networks about AI-powered cancer research and the importance of diverse, high-quality data.

We launched our On the Horizon event series to connect industry and investors with cutting-edge science, starting with extrachromosomal DNA.

Pat LoRusso lost both her parents to cancer and went on to help get 26 new treatments approved. Lars Erwig speaks to her about her career.

Joy Shih reports back from the Eureka Institute’s translational medicine course in Syracuse, Sicily.

Lian Ni Lee, Julie Mead, Catherine Pickering and Annelise Soulier share their experiences of building companies to develop new cancer treatments.

Insights from the J.P. Morgan Healthcare Conference, from the biggest deals to the hottest trends.

Our colleagues across Cancer Research Horizons share the opportunities and threats that 2025 may bring to their areas of expertise.

Shefali Bohra and Debra Babalola share how they put their users at the centre of their creative process to help detect signs of breast cancer.

The Functional Genomics Centre generates vast amounts of CRISPR data every day. Here’s how they’re building a database to make sense of it all.

CEO and founder of Carcinotech, Ishani Malhotra, talks about what it's like to start your own company and why Edinburgh is a great place to do it in.

GambitBio's co-founder, Tiffany Ma, explains how they're developing an at-home lateral flow test to screen for the most common cancers.

CEO and co-founder Rory Ryan explains how PentaBind uses generative AI to develop aptamers that could target previously undruggable human proteins.

Investors in residence, Genghis Lloyd Harris and Jonathan Tobin discuss the current market and how their roles fit into it.

Hear from Lars Erwig, Director of Cancer Research UK’s Centre for Drug Development on the need for global collaboration in clinical trials.

To mark #IWD24, hear from some of our scientists about their professional journeys and advice for women embarking on a career in STEM.

Hear from CEO, Iain Foulkes, about the power of data partnerships.

Hear from Sophia Karagiannis and James Spicer on their journey to get the first IgE anti-cancer drug into humans.

Read our reflections on the Government's independent review of the UK spinout landscape.

Read about MOv18, the first IgE antibody to enter clinical development.

Find out how single-cell CRISPR capability advances drug discovery through genotype to phenotype correlation.

Our medicinal chemists review the hydroxylation of steroids, detailing discoveries in the beautiful, complicatedly chiral world of steroid chemistry.

Read about the DETERMINE trial and how it aims to address the limited treatments available for people with rare cancers.

Learn how cancer patient-derived organoids from Japan’s Fukushima Medical University became the latest tech to be made available via CancerTools.org.

Five innovations from the world’s greatest minds in microbiology, astronomy and programming that could transform the way we deal with cancer.

Our Chief Business Officer, Tony Hickson, explores how we contribute to the economic impact of Cancer Research UK-funded research in the UK.

The story of gamma delta T cells from discovery to clinical trials

From discovery to translation - the story of pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in cancers.

The OPTIMAM project’s mammogram collection is heralding a new dawn of machine-learning-based cancer detection.

How scientific expertise, funding and entrepreneurship came together for the development of an antibody-drug conjugate targeting lymphoma

Guided by Cancer Research Horizons in collaboration with Roche, Cancer Research UK scientists develop a new antibody that can target CD25.

Monika Gullerova is a scientist first and foremost. She saw an opportunity to develop her research idea to have real-world impact.

Jason Mellad co-founded Start Codon to support teams in translating their research ideas through seed funding, guidance and access to partners.

Anna Perdix Rosell co-founded biotech start-up, Sixfold Bioscience, in the hopes of addressing the challenge of delivering drugs to cancer cells.

Read how researchers supported by Cancer Research UK deciphered how blocking DNA repair could expose a weak point in the biology of cancer cells.

View our latest press releases including updates from our parent organisation Cancer Research UK and partner organisations.

Through our network, you can access a range of scientific conferences, networking and other events aimed at researchers, partners and investors.

Here you can find podcasts, video interviews, whitepapers and webinars to learn more about what we do, and how you can work with us.